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Abstract: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of coronavirus
disease 2019 (COVID-19), is a recently emerged respiratory coronavirus that has infected >23 million
people worldwide with >800,000 deaths. Few COVID-19 therapeutics are available, and the basis for
severe infections is poorly understood. Here, we investigated properties of type I (฀), II (฀), and III
(฀1) interferons (IFNs), potent immune cytokines that are normally produced during infection and that
upregulate IFN-stimulated gene (ISG) effectors to limit virus replication. IFNs are already in clinical
trials to treat COVID-19. However, recent studies highlight the potential for IFNs to enhance expression
of host angiotensin-converting enzyme 2 (ACE2), suggesting that IFN therapy or natural coinfections
could exacerbate COVID-19 by upregulating this critical virus entry receptor. Using a cell line model,
we found that beta interferon (IFN-฀) strongly upregulated expression of canonical antiviral ISGs, as well
as ACE2 at the mRNA and cell surface protein levels. Strikingly, IFN-฀1 upregulated antiviral ISGs, but
ACE2 mRNA was only marginally elevated and did not lead to detectably increased ACE2 protein at the
cell surface. IFN-฀ induced the weakest ISG response but clearly enhanced surface expression of ACE2.
Importantly, all IFN types inhibited SARS-CoV-2 replication in a dose-dependent manner, and IFN-฀
and IFN-฀1 exhibited potent antiviral activity in primary human bronchial epithelial cells. Our data
imply that type-specific mechanisms or kinetics shape IFN-enhanced ACE2 transcript and cell surface
levels but that the antiviral action of IFNs against SARS-CoV-2 counterbalances any proviral effects of
ACE2 induction. These insights should aid in evaluating the benefits of specific IFNs, particularly IFN-฀,
as repurposed therapeutics.IMPORTANCE Repurposing existing, clinically approved, antiviral drugs as
COVID-19 therapeutics is a rapid way to help combat the SARS-CoV-2 pandemic. Interferons (IFNs)
usually form part of the body’s natural innate immune defenses against viruses, and they have been used
with partial success to treat previous new viral threats, such as HIV, hepatitis C virus, and Ebola virus.
Nevertheless, IFNs can have undesirable side effects, and recent reports indicate that IFNs upregulate
the expression of host ACE2 (a critical entry receptor for SARS-CoV-2), raising the possibility that IFN
treatments could exacerbate COVID-19. Here, we studied the antiviral- and ACE2-inducing properties
of different IFN types in both a human lung cell line model and primary human bronchial epithelial cells.
We observed differences between IFNs with respect to their induction of antiviral genes and abilities to
enhance the cell surface expression of ACE2. Nevertheless, all the IFNs limited SARS-CoV-2 replication,
suggesting that their antiviral actions can counterbalance increased ACE2.
DOI: https://doi.org/10.1128/mBio.01928-20
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ABSTRACT Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the
cause of coronavirus disease 2019 (COVID-19), is a recently emerged respiratory
coronavirus that has infected 23 million people worldwide with 800,000 deaths.
Few COVID-19 therapeutics are available, and the basis for severe infections is
poorly understood. Here, we investigated properties of type I (), II (), and III (1)
interferons (IFNs), potent immune cytokines that are normally produced during in-
fection and that upregulate IFN-stimulated gene (ISG) effectors to limit virus replica-
tion. IFNs are already in clinical trials to treat COVID-19. However, recent studies high-
light the potential for IFNs to enhance expression of host angiotensin-converting
enzyme 2 (ACE2), suggesting that IFN therapy or natural coinfections could exacer-
bate COVID-19 by upregulating this critical virus entry receptor. Using a cell line
model, we found that beta interferon (IFN-) strongly upregulated expression of ca-
nonical antiviral ISGs, as well as ACE2 at the mRNA and cell surface protein levels.
Strikingly, IFN-1 upregulated antiviral ISGs, but ACE2 mRNA was only marginally el-
evated and did not lead to detectably increased ACE2 protein at the cell surface.
IFN- induced the weakest ISG response but clearly enhanced surface expression of
ACE2. Importantly, all IFN types inhibited SARS-CoV-2 replication in a dose-dependent
manner, and IFN- and IFN-1 exhibited potent antiviral activity in primary human
bronchial epithelial cells. Our data imply that type-specific mechanisms or kinetics
shape IFN-enhanced ACE2 transcript and cell surface levels but that the antiviral ac-
tion of IFNs against SARS-CoV-2 counterbalances any proviral effects of ACE2 induc-
tion. These insights should aid in evaluating the benefits of specific IFNs, particularly
IFN-, as repurposed therapeutics.
IMPORTANCE Repurposing existing, clinically approved, antiviral drugs as COVID-19
therapeutics is a rapid way to help combat the SARS-CoV-2 pandemic. Interferons
(IFNs) usually form part of the body’s natural innate immune defenses against vi-
ruses, and they have been used with partial success to treat previous new viral
threats, such as HIV, hepatitis C virus, and Ebola virus. Nevertheless, IFNs can have
undesirable side effects, and recent reports indicate that IFNs upregulate the expres-
sion of host ACE2 (a critical entry receptor for SARS-CoV-2), raising the possibility
that IFN treatments could exacerbate COVID-19. Here, we studied the antiviral- and
ACE2-inducing properties of different IFN types in both a human lung cell line
model and primary human bronchial epithelial cells. We observed differences be-
tween IFNs with respect to their induction of antiviral genes and abilities to enhance
the cell surface expression of ACE2. Nevertheless, all the IFNs limited SARS-CoV-2
replication, suggesting that their antiviral actions can counterbalance increased
ACE2.
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Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the etiologicalagent of coronavirus disease 2019 (COVID-19), a new infectious respiratory disease
characterized by a broad range of symptoms categorized as mild (fever, cough, mild
pneumonia), severe (labored breathing [dyspnea], respiratory distress, and pneumonia),
or critical (respiratory failure, septic shock, and multiple organ failure) (1, 2). Since its
presumed emergence in late 2019, pandemic SARS-CoV-2 has caused over 23 million
laboratory-confirmed human infections worldwide, and at least 800,000 deaths (3),
predominantly in those over 70 years of age or with preexisting comorbidities, such as
cardiovascular disease, diabetes, chronic respiratory disease, hypertension, or cancer
(2). There are currently no specific licensed antiviral treatments or proven vaccines
available for COVID-19, and the molecular basis for many severe SARS-CoV-2 infections
is poorly understood.
Angiotensin-converting enzyme 2 (ACE2) is the essential receptor for SARS-CoV-2
entry into host cells (4, 5), and it is therefore a critical determinant of viral replication
and pathogenesis. ACE2 protein is not expressed by all human cells, but it has been
found in high abundance on the surfaces of type II alveolar epithelial cells (AT2
pneumocytes) in the lower parts of the human respiratory tract (6) and at low levels on
ciliated airway epithelial cells of the nose and trachea (7). Recent single-cell sequence
analysis efforts have sought to systematically identify specific human cell subsets that
express ACE2 mRNA (8–10), with the aim of determining the precise cellular tropism of
SARS-CoV-2 and linking this with pathology. Intriguingly, ACE2mRNA levels also appear
to be regulated by a multitude of factors, including age (11), tobacco smoke (12), and
other respiratory tract infections (e.g., rhinovirus and influenza virus) (9) potentially via
the canonically antiviral type I and II interferon (IFN) pathways (9, 12, 13). Thus, a
tempting hypothesis that remains to be experimentally validated is that external or
biological factors leading to enhanced ACE2 expression may exacerbate SARS-CoV-2
replication and/or expand its cellular tropism (14), thereby increasing the severity of
COVID-19 in individuals of certain risk groups, including the elderly, smokers, and those
with coinfections or comorbidities (15).
Type I and III IFNs restrict SARS-CoV-2 replication in primary human bronchial
epithelial cells. Given that many respiratory viruses cocirculating with SARS-CoV-2
(such as influenza virus, rhinovirus, or seasonal coronaviruses) can trigger host IFN
production, as well as the recent repurposing of IFNs in clinical trials as COVID-19
therapeutics (16), we sought to understand the interplay between the antiviral action
of IFNs (17), the IFN-stimulated expression of ACE2 (9, 12, 13), and SARS-CoV-2
replication. As ACE2 expression was reported to be predominantly induced by type I
and II IFNs in primary human cells (9), we first established a primary human bronchial
epithelial cell (BEpC) SARS-CoV-2 infection model. BEpCs were grown at an air-liquid
interface (ALI) and validated for their differentiation into a pseudostratified respiratory
epithelium by measuring increased transepithelial electrical resistance (TEER) and
presence of epithelium-specific cell and tight junction markers, such as -tubulin and
zona occludens protein 1 (ZO-1) (Fig. 1A and B). We found that these differentiated
human BEpCs were highly permissive to SARS-CoV-2 replication when infected from
the apical side, mimicking the natural route of initial infection, and viral titers reached
in excess of 107 PFU/ml at 72 h postinfection (Fig. 1C). The BEpCs could readily mount
an antiviral gene expression profile (e.g., increased MX1 and RSAD2) following 16 h
stimulation with type I (), II (), or III (1) IFNs, but surprisingly, we did not observe
induction of ACE2 with any of the IFNs tested, in contrast to other recent reports (9, 12,
13) (Fig. 1D). We note that our BEpC donor was a 73-year-old “never-smoker” and that
age can correlate with ACE2 levels (11), presumably via an IFN-independent mecha-
nism, leading us to hypothesize that the lack of ACE2 induction by IFNs in our BEpC
system could be due to relatively high basal levels saturating potential expression
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changes. Nevertheless, pretreatment of BEpCs with type I and III, but not type II, IFNs
for 16 h lead to a clear reduction in SARS-CoV-2 replication following apical side
infection (Fig. 1E). Furthermore, at 72 h postinfection, a small amount of infectious
SARS-CoV-2 was detected on the basolateral side of the BEpC cultures in the absence
of treatment, but this was blocked by type I and III IFNs (Fig. 1F). These data indicate
that type I and III IFNs exert potent IFN-stimulated gene (ISG) induction and antiviral
activity against SARS-CoV-2 in primary human bronchial epithelial cells.
IFN-induced ACE2 is not sufficient to enhance SARS-CoV-2 replication in the
presence of IFN-induced antiviral activity.We tested the hypothesis that lack of ACE2
induction by IFNs in the primary BEpC cultures was due to relatively high basal levels
saturating potential changes. Indeed, by comparative real-time quantitative PCR (RT-
qPCR) analysis of ACE2 in primary BEpCs and the human lung epithelial cell line model
Calu-3, we noted that basal expression of ACE2 at the bulk population level was
FIG 1 Replication of SARS-CoV-2 in primary human differentiated bronchial epithelial cells and its restriction by type I, II,
and III interferons. (A) Primary human bronchial epithelial cells (BEpCs) were differentiated and grown at an air-liquid
interface (ALI) for 28 days. TEER was monitored at the time points indicated, with data representing means  standard
deviations (error bars) from three independent wells. (B) Differentiated BEpCs were fixed and stained for ciliated cells
(-tubulin; turquoise), tight junctions (ZO-1; magenta) and nuclei (4=,6=-diamidino-2-phenylindole [DAPI]; blue). Bars,
25 m. (C) Differentiated BEpCs grown on 6.5-mm filter inserts were infected with 6,000 PFU of SARS-CoV-2 from the apical
side. At the indicated times postinfection, apical washes were harvested and virus titers were determined by plaque assay.
Data represent means plus standard deviations from two independent replicates. (D) Differentiated BEpCs were treated on
the apical side with 1,000 IU/ml type I (), type II (), or type III (1) IFN (or left untreated [Untr.]) for 16 h before total RNA
was harvested and the levels of MX1, RSAD2 and ACE2 were quantified by RT-qPCR. Data represent means plus standard
deviations from two independent replicates. (E and F) Differentiated BEpCs were treated with 1,000 IU/ml type I (), type
II (), or type III (1) IFN (or left untreated) for 16 h prior to infection with 6,000 PFU of SARS-CoV-2 from the apical side.
At the indicated times postinfection, apical washes (E) and basolateral samples (F) were harvested and virus titers were
determined by plaque assay. Data represent means plus standard deviations from two independent replicates. The limit
of detection (LoD) is indicated by the dotted lines.
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substantially higher in the primary BEpCs than in Calu-3 cells (Calu-3s) (Fig. 2A).
Furthermore, stimulation of Calu-3s with type I IFN for 16 h led to a dose-dependent
induction of ACE2 gene expression, increasing ACE2mRNA levels approximately 20-fold
(Fig. 2B). Calu-3 cells were also found to be susceptible to SARS-CoV-2 infection (see
Fig. S1A in the supplemental material), and consistent with a previous report (18),
SARS-CoV-2 infection triggered blunted type I/III IFN responses in these cells as defined
by levels of IFNB1, IFNL1, MX1, and RSAD2 (Fig. S1B to E). Consistent with this,
SARS-CoV-2 infection alone was also unable to induce ACE2 mRNA levels, unlike type
I IFN (Fig. S1F). We therefore used Calu-3s as an amenable cell line model with
IFN-inducible ACE2 to dissect the interplay between IFNs, ACE2, and SARS-CoV-2
further.
While type I, II, and III IFNs all induced canonical ISGs (such as MX1 and RSAD2) in
Calu-3s, there was a gradient to this response, with type I IFN being a more potent or
rapid inducer than type III IFN and type II IFN inducing the lowest levels of ISGs. A
similar pattern was noted for IFN-induced ACE2, although ACE2 induction at the mRNA
level was not detectable for type II IFN, and it was slightly increased for type III IFN
albeit this did not reach statistical significance (Fig. 2B). To understand whether ACE2
mRNA induction translated into increased ACE2 protein levels on the surfaces of cells,
we analyzed IFN-treated Calu-3 cells by fluorescence-activated cell sorting (FACS).
While type I IFN potently induced ACE2 mRNA at 16 h posttreatment, we could detect
increased cell surface expression of ACE2 protein only after treatment of cells for 72 h,
and not for earlier time points (Fig. 2C). In line with the low induction of ACE2 mRNA
by type III IFN, we were unable to detect ACE2 cell surface expression following
treatment with this IFN, even after 72 h treatment (Fig. 2D and E). Surprisingly, type II
IFN, which did not lead to detectable induction of the ACE2 gene (Fig. 2B), clearly
increased cell surface expression levels of ACE2 protein in Calu-3s after 72 h treatment
(Fig. 2D and E), suggesting either different kinetics for ACE2mRNA induction by this IFN
or a transcription-independent mechanism for protein upregulation. Indeed, kinetic
and dose-response analyses of a wide range of canonical ISGs and ACE2 after type I and
III IFN treatments revealed that type I IFN induced faster and greater gene expression
responses than type III IFN, though following comparable gene induction type III
responses appeared to be of longer duration (Fig. 2F and Fig. S2A to C). Importantly,
expression of the canonical antiviral ISG marker protein, MxA, was maintained through-
out the prolonged IFN treatment time necessary to detect enhanced surface expression
of ACE2 (Fig. 2G and H). We therefore pretreated Calu-3s for 72 h with each of the IFNs
in a dose-dependent manner with the aim of inducing different levels of ACE2 cell
surface expression, as well as the canonical antiviral ISG program, prior to infection with
SARS-CoV-2. Strikingly, treatment with type I, II, and III IFNs all inhibited the replication
of SARS-CoV-2 in Calu-3s, despite the previously observed enhanced ACE2 cell surface
expression caused by type I and II IFNs (Fig. 2I). Notably, SARS-CoV-2 replication in the
Calu-3 cell model system in the absence of IFN was relatively low (reaching only 104
PFU/ml at 24 h postinfection), suggesting that an increase in virus replication caused by
enhanced ACE2 expression would have been detected in our set-up. These data
indicate that, while IFNs can upregulate ACE2 at both the gene expression and cell
surface levels, the antiviral action of IFNs is more powerful and counterbalances ACE2
induction to restrict SARS-CoV-2 replication.
Concluding remarks. Due to the lack of antiviral drugs that specifically target the
newly emerged SARS-CoV-2, rapid repurposing of existing licensed drugs with other
modes of action is a critical tool to combat the pandemic. IFNs are pleotropic cytokines
that exhibit broad-spectrum antiviral activity through the upregulation of hundreds of
ISGs; therefore, IFN therapy could be a treatment option for COVID-19 patients. To date,
type I IFNs (IFN-2b, IFN-1a, and IFN-1b) and type III IFN (IFN-1a) have all begun
clinical trials as potential COVID-19 therapeutics (16, 19, 20). However, several recent
studies have indicated that IFNs upregulate the expression of ACE2 (9, 12, 13), the
critical SARS-CoV-2 receptor (4), suggesting that IFN treatments could have the poten-
Busnadiego et al. ®













































FIG 2 Antiviral activity of type I, II, and III interferons counterbalances ACE2 induction to restrict SARS-CoV-2 replication
in Calu-3 cells. (A) Basal ACE2 mRNA expression in BEpCs and Calu-3 cells was measured by RT-qPCR, and the levels in
BEpCs were set at 100% for comparison. Data represent means  standard deviations from three independent BEpC
samples and five independent Calu-3 samples. (B) Calu-3 cells were treated with 10, 100, or 1,000 IU/ml of type I (), type
II (), or type III (1) IFN (or left untreated [Untr.]) for 16 h before total RNA was harvested and mRNA levels of MX1, RSAD2,
and ACE2 were determined by RT-qPCR. Data represent means plus standard deviations from three independent replicates.
Statistical significance was determined for cells treated with each IFN compared to untreated cells using two-way ANOVA
following log transformation (ns, not significant; *, P  0.05; **, P  0.002; ***, P  0.0002; ****, P  0.0001). (C) Calu-3 cells
were treated with 1,000 IU/ml of IFN- for 24 h (left) or 72 h (right) before ACE2 surface levels were assessed by FACS. (D)
Calu-3 cells were treated with 1,000 IU/ml of IFN- (left) or IFN-1 (right) for 72 h before ACE2 surface levels were assessed
by FACS. (E) Mean fluorescence intensity (MFI) values from Calu-3 cells treated with 1,000 IU/ml of type I (), type II (),
or type III (1) IFN (or left untreated [Untr.]) for 72 h and analyzed by FACS for ACE2 surface levels. Data represent means
plus standard deviations from three independent replicates. The limit of detection (LoD) is indicated by the dotted line.
Statistical significance was determined for cells treated with each IFN compared to untreated cells by one-way ANOVA (ns,
not significant; **, P  0.0002). (F) Calu-3 cells were treated with the indicated amounts of type I () or type III (1) IFN (or
left untreated [Untr.]) before total RNA was harvested at the indicated times and mRNA levels of MX1, RSAD2, and ACE2
were determined by RT-qPCR. Data represent means plus standard deviations from three independent replicates. (G and
H) Calu-3 cells treated for 24 h (G) or 72 h (H) with 10, 100, or 1,000 IU/ml of type I (), type II (), or type III (1) IFN (or
left untreated [Untr.]) were lysed, and the levels of MxA and actin were determined by Western blotting. Data shown are
(Continued on next page)
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tial to exacerbate virus replication under some circumstances. The data presented here
confirm that IFNs can induce ACE2 mRNA expression and further suggest type-specific
differences between IFNs with respect to their promotion of ACE2 protein expression
at the cell surface, the site relevant for infection. The molecular basis for these
differences between IFNs, or whether differences simply reflect the speed, magnitude,
and duration of individual responses, remains to be dissected. Nevertheless, in both the
Calu-3 cell line model and primary human bronchial epithelial cells, IFNs exhibited
inhibitory activity against SARS-CoV-2, indicating that the antiviral function of IFNs
counterbalances any possible replication-promoting benefit of increased ACE2 expres-
sion. While these findings cannot necessarily be extrapolated to all biological tissue
types or other in vivo conditions, together with similar recent studies (21–23), they do
support the concept that selected IFNs could be used as short-term antiviral therapies
until new specific, potent COVID-19 drugs are developed (16). Notably, IFN-, which has
critical antiviral functions in the respiratory and gastrointestinal tracts (22, 24) and
which appears to exhibit less detrimental proinflammatory effects compared to other
IFNs (25), did not induce a detectable increase in ACE2 protein cell surface expression
in our hands, despite sustained canonical antiviral ISG induction. This may add weight
to proposals that IFN- is a superior therapeutic candidate against SARS-CoV-2 than
other IFNs.
Experimental procedures. (i) Cell lines and interferons. Calu-3 and Vero-CCL81
cells (ATCC) were cultured at 37°C and 5% CO2 in Dulbecco’s modified Eagle’s medium
(DMEM; Gibco), supplemented with 10% (vol/vol) fetal calf serum (FCS), 100 U/ml of
penicillin, and 100 g/ml of streptomycin (catalog no. 15140-122; Gibco). Recombinant
IFN-2 (catalog no. NBP2-34971; Novusbio), IFN-1b (catalog no. NBP2-35892; Novus-
bio), IFN- (catalog no. NBP2-34992; Novusbio), and IFN-1 (catalog no. 300-02L;
Peprotech) were used at the indicated concentrations. For pretreatment of primary
human bronchial epithelial cells (BEpCs), IFNs were added to the apical compartment
in phosphate-buffered saline (PBS). All incubations were performed at 37°C.
(ii) Differentiation of primary human bronchial epithelial cultures. Primary
human bronchial epithelial cells from a 73-year-old female donor were purchased from
Promocell (catalog no. C-12640). Cells were grown in airway epithelium basal growth
medium (catalog no. C-21260l; Promocell) supplemented with an airway growth me-
dium supplement pack (catalog no. C-39160; Promocell) and 10 M Y-27632 (Selleck
Chemicals). For differentiation, transwell plates with 6.5-mm polyester filter inserts
(catalog no. CLS3470; Corning) were coated with collagen: a 0.5-mg/ml collagen
(catalog no. C7774; Sigma-Aldrich) stock in 0.5 M acetic acid (catalog no. 100063.1000;
Merck) was diluted to 0.15 mg/ml in PBS prior to coating the filters. BEpCs were seeded
onto the coated transwell filters in a 1:1 mixture of airway epithelium basal growth
medium and DMEM, which was supplemented with an airway growth medium sup-
plement pack, and cells were grown until confluence was reached. For differentiation
at the air-liquid interface (ALI), medium was removed from the apical compartment,
and the medium in the basal compartment was supplemented with 150 ng/ml retinoic
acid (catalog no. R2625; Sigma-Aldrich). BEpCs were cultured at ALI for a minimum of
28 days prior to use, and medium in the basal compartment was refreshed every 3 days.
(iii) Validation of differentiated primary human bronchial epithelial cultures.
Differentiation of the airway cultures was verified by regularly measuring the transep-
ithelial electrical resistance (TEER) using an ERS-2 meter (Millicell). In addition, the
presence of ciliated cells and tight junctions was verified by immunofluorescence.
FIG 2 Legend (Continued)
representative of two independent replicates. (I) Calu-3 cells treated for 72 h with 10, 100, or 1,000 IU/ml of type I (), type
II (), or type III (1) IFN (or left untreated [Untr.]) were infected with SARS-CoV-2 at an MOI of 1 PFU/cell. Virus was
harvested at 24 h postinfection, and titers were determined by plaque assay. Data represent means plus standard
deviations from three independent replicates. Statistical significance was determined for cells treated with each IFN
compared to untreated cells by two-way ANOVA following log transformation (ns, not significant; *, P  0.05; **, P  0.002;
****, P  0.0001).
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Briefly, cells were fixed with 3.7% paraformaldehyde in PBS and permeabilized with PBS
supplemented with 50 mM ammonium chloride (catalog no. 254134; Sigma-Aldrich),
0.1% saponin (catalog no. 47036; Sigma-Aldrich) and 2% bovine serum albumin (BSA)
(catalog no. A7906; Sigma-Aldrich). A mouse anti--tubulin IV antibody (ab11315;
Abcam) and a rabbit anti-ZO-1 antibody (catalog no. 61-7300; Thermo Fisher Scientific)
were used to stain ciliated cells and tight junctions, respectively. As secondary anti-
bodies, anti-mouse IgG Alexa Fluor 488 and anti-rabbit IgG Alexa Fluor 546 antibodies
(catalog no. A-21202 and catalog no. A-11035; Thermo Fisher Scientific) were used.
Filters were mounted using ProLong Gold Antifade Mountant (catalog no. P36930;
Thermo Fisher Scientific), and images were acquired on an SP5 confocal microscope
(Leica).
(iv) SARS-CoV-2 isolation and stocks. SARS-CoV-2 (strain IMV5 [SARS-CoV-2/hu-
man/Switzerland/IMV5/2020]) was isolated on Vero-CCL81 cells from an anonymized
patient nasopharyngeal swab sample that had tested PCR positive during routine
diagnostics at the Institute of Medical Virology, University of Zurich in March 2020.
Briefly, 100 l of a fivefold dilution series of sample in serum-free DMEM was mixed
with 1  105 Vero-CCL81 cells in 500 l of DMEM supplemented with 10% FCS, 100
U/ml penicillin, 100 g/ml streptomycin, and 2.5 g/ml amphotericin B (catalog no.
15290018; Gibco). Cells were seeded in 24-well plates and incubated at 37°C for 4 to
5 days until cytopathic effect was apparent. Supernatants were centrifuged at
1,500 rpm for 5 min, and 250 l of this cleared supernatant (termed passage 1 [P1]) was
used to inoculate a 25-cm2 flask of freshly seeded Vero-CCL81 cells, which were then
cultured in the same way for a further 4 or 5 days at 37°C. Cell supernatants were
harvested, clarified by centrifugation at 1,500 rpm for 5 min, and aliquoted before
freezing at 80°C (termed P2). P2 stocks were verified by our in-house diagnostics
service to be PCR positive for SARS-CoV-2. Following titer determination by plaque
assay (see below), a P3 working stock was generated by infecting Vero-CCL81 cells at
a multiplicity of infection (MOI) of 0.001 PFU/cell for 72 h in DMEM supplemented with
100 U/ml penicillin, 100 g/ml streptomycin, 0.3% bovine serum albumin (BSA) (catalog
no. A7906; Sigma-Aldrich), 20 mM HEPES (catalog no. H7523; Sigma-Aldrich), 0.1% FCS,
and 0.5 g/ml tosylsulfonyl phenylalanyl chloromethyl ketone (TPCK)-treated trypsin
(catalog no. T1426; Sigma-Aldrich), prior to supernatant clarification by centrifugation
(1,500 rpm, 5 min), aliquoting/storage at 80°C, and plaque titration. All work with
infectious SARS-CoV-2 was performed in an approved biosafety level 3 (BSL3) facility by
trained personnel at the Institute of Medical Virology, University of Zurich. All proce-
dures and protective measures were thoroughly risk assessed prior to starting the
project and were approved by the Swiss Federal Office of Public Health (Ecogen
number A202808/3).
(v) SARS-CoV-2 plaque assays. To determine SARS-CoV-2 titers by plaque assay,
Vero-CCL81 cells in 12-well plates were infected with 100 l of 10-fold serial dilutions
of sample in PBS supplemented with 0.3% BSA, 1 mM Ca2/Mg2, 100 U/ml penicillin,
and 100 g/ml streptomycin. After 1 h at 37°C with regular rocking, inoculum was
removed and replaced with 1 ml/well of agar overlay (MEM; 0.1% sodium bicarbonate,
0.01% DEAE dextran, 0.6% oxoid agar, and 1 mg/ml TPCK-trypsin). Once the overlay had
solidified, plates were incubated at 37°C for 72 h prior to fixing with 3.7% formaldehyde
in PBS. Cell monolayers were stained with crystal violet (0.5% crystal violet and 20%
methanol) to visualize plaques.
(vi) SARS-CoV-2 infection assays. For Calu-3 experiments, 5  104 cells were
seeded overnight in 24-well plates before treatment with the indicated IFN. Cells were
then infected with SARS-CoV-2 at the indicated MOI in PBS supplemented with 0.3%
BSA, 1 mM Ca2/Mg2, 100 U/ml penicillin, and 100 g/ml streptomycin. After 1 h
inoculation, cells were washed once in PBS, and the medium was replaced with DMEM
supplemented with 100 U/ml penicillin, 100 g/ml streptomycin, 0.3% BSA, 20 mM
HEPES, 0.1% FCS, and 0.5 g/ml TPCK-treated trypsin. Samples were taken at the
indicated time points, and supernatants were stored at 80˚C prior to titer determi-
nation. For BEpC experiments, cells were infected from the apical side with 6,000 PFU
IFNs, ACE2, and SARS-CoV-2 ®













































SARS-CoV-2 in PBS supplemented with 0.3% BSA, 1 mM Ca2/Mg2, 100 U/ml penicil-
lin, and 100 g/ml streptomycin. After 1 h, the inoculum was removed, and cells were
incubated at 37°C. At selected time points, virus was harvested from the apical side by
applying 80 l of PBS for 15 min at 37°C before removal and storage at 80°C prior to
titer determination. Basolateral samples were also collected and frozen at 80˚C.
(vii) Assessment of RNA levels by RT-qPCR. Total RNA was extracted from cells
using the ReliaPrep RNA cell miniprep system (Promega) according to the manufac-
turer’s instructions. cDNA was synthesized from 1 g of total RNA using Superscript III
reverse transcriptase (Thermo Fisher) and oligo(dT)15 primer (Promega). RT-qPCR was
performed on a 7300 real-time PCR system (Applied Biosystems) using Fast EvaGreen
qPCR master mix kit (Biotium) and the following primers: for MX1, Hs.PT.58.26787898
(Integrated DNA Technologies); for RSAD2, 5=-CCCCAACCAGCGTCAACTAT-3= and 5=-T
GATCTTCTCCATACCAGCTTCC-3=; for ACE2, 5=-GGCTTGGGAAAGCTGGAGAT-3= and 5=-G
GGATGGCAGACTGCTTTCT-3=; for IFNB1, 5=-CATTACCTGAAGGCCAAGGA-3= and 5=-CAG
CATCTGCTGGTTGAAGA-3=; for IFNL1, 5=-GGTGACTTTGGTGCTAGGCT-3= and 5=-TGAGTG
ACTCTTCCAAGGCG-3=; for DDX58, 5=-TGCAAGCTGTGTGCTTCTCT-3= and 5=-TCCTGAAA
AACTTCTGGGGCT-3=; for IFIT1, 5=-CTGTGGTAGGCTCTGCTTCC-3= and 5=-CCACCACACCC
AGCTAAGTT-3=; for IFIT2, 5=-GCGTGAAGAAGGTGAAGAGG-3= and 5=-GCAGGTAGGCATT
GTTTG-3=. The delta delta- cycle threshold (ΔΔCt) was determined relative to untreated
or mock-infected samples. Gene expression was normalized to glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) (5=-CTGGCGTCTTCACCACCATGG-3= and 5=-CATCA
CGCCACAGTTTCCCGG-3=). qPCR for the SARS-CoV-2 E gene was performed by our
in-house diagnostics service using the TaqMan method (26) and the following primers:
5=-ACAGGTACGTTAATAGTTAATAGCGT-3= (forward [fwd]), 5=-ATATTGCAGCAGTACGCA
CACA-3= (reverse [rev]), and 5=-ACACTAGCCATCCTTACTGCGCTTCG-3= (probe).
(viii) Assessment of ACE2 cell surface levels by flow cytometry. Following the
appropriate treatment, 2  105 Calu-3 cells were detached from 24-well plates with
0.25% trypsin-EDTA (Thermo Fisher Scientific) and resuspended in DMEM supple-
mented with 10% FCS and penicillin-streptomycin. Cells were washed twice with FACS
buffer (PBS supplemented with 1 mM EDTA [Thermo Fisher Scientific] and 2% BSA
[Sigma-Aldrich]) by centrifugation at 1,100 rpm for 3 min at 4°C and resuspension of cell
pellets. To stain for surface ACE2, cells were incubated in 50 l FACS buffer containing
4 g/ml of anti-human ACE2 antibody (catalog no. AF933-SP; R&D Systems) and
10 g/ml rabbit anti-goat IgG (HL) cross-adsorbed secondary antibody, DyLight 488
(catalog no. SA5-10078; Thermo Fisher Scientific), for 1 h at 4°C. To exclude dead cells,
stain from a LIVE/DEAD Fixable Near-IR Dead Cell Stain kit (Thermo Fisher Scientific) was
used at a dilution of 1:1,000. Cells were further washed three times with FACS buffer,
resuspended in 200 l of FACS buffer, and analyzed on a FACSVerse system (BD).
Typically, 3  103 to 5  103 live cells were acquired, and fluorescein isothiocyanate
(FITC) intensities were examined.
(ix) SDS-PAGE and Western blotting. Cell lysates were prepared in 2 urea
disruption buffer (6 M urea, 4% sodium dodecyl sulfate [SDS], 1 M -mercaptoethanol,
bromophenol blue), sonicated, and heated to 95°C for 5 min. Proteins were separated
by SDS-polyacrylamide gel electrophoresis (PAGE) on 4 to 12% NuPAGE Bis-Tris gradi-
ent gels (Life Technologies) and transferred to nitrocellulose membranes (GE Health-
care, Amersham). The indicated proteins were detected using antibodies specific for
MxA (mouse ab143; kindly provided by Jovan Pavlovic), or actin (rabbit) (catalog no.
A2103; Sigma-Aldrich). The secondary antibodies used were IRDye 800CW goat anti-
mouse IgG (catalog no. 926-32210; Li-Cor) and IRDye 680RD goat anti-rabbit IgG
(catalog no. 926-68071; Li-Cor). A Li-Cor Odyssey scanner was used for detection.
(x) Statistical analyses. Statistical analyses were performed using GraphPad Prism
8.4 (GraphPad Software, San Diego, CA, USA). Data were log transformed and analyzed
by either one-way or two-way analysis of variance (ANOVA) for multiple comparisons.
P values for significance are given in the figure legends.
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